Total Voting Rights and Block Listing Return
Total Voting Rights
Guildford, UK - 4 January 2022: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.
The Company's issued share capital as at 31 December 2021 consisted of 49,138,071 ordinary shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.
Block Listing Six Monthly Return
| Name of applicant: | Ergomed plc | |||
| Name of scheme: | Ergomed plc Long Term Incentive Plan | |||
| Period of return: | From: | 1 July 2021 | To: | 31 December 2021 |
| Balance of unallotted securities under scheme(s) from previous return: | 1,466,400 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 600,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 158,223 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,908,177 | |||
| Number and class of securities originally admitted and the date of admission | 1,800,000 ordinary shares of 1p each - 2 July 2018 1,500,000 ordinary shares of 1p each - 31 December 2019 600,000 ordinary shares of 1p each - 7 July 2021 | |||
| Total number of securities in issue at the end of the period | 49,138,071 ordinary shares of 1p each | |||
| Name of contact: | Nick Roberts - Head of Group Reporting |
| Telephone number of contact: | +44 (0) 1483 503 205 |
ENDS
Enquiries:
| Ergomed plc | Tel: +44 (0) 1483 402 975 |
| Miroslav Reljanović (Executive Chairman) | |
| Richard Barfield (Chief Financial Officer) | |
| | |
| Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
| Freddie Barnfield / Matthew O'Dowd (Nominated Adviser) | |
| James Black (Broker) | |
| | |
| Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
| Chris Gardner / Matthew Neal | ergomed@consilium-comms.com |
| Angela Gray / Lucy Featherstone | |
| | |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
